Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 1069mg equivalent to cyclophosphamide anhydrous 1000 mg;   - powder for injection - 1000 mg - active: cyclophosphamide monohydrate 1069mg equivalent to cyclophosphamide anhydrous 1000 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg;   - powder for injection - 2000 mg - active: cyclophosphamide monohydrate 2138mg equivalent to cyclophosphamide anhydrous 2000 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - cyclophosphamide monohydrate 534.5mg equivalent to cyclophosphamide anhydrous 500 mg;   - powder for injection - 500 mg - active: cyclophosphamide monohydrate 534.5mg equivalent to cyclophosphamide anhydrous 500 mg   - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient's general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.

Namibia - englanti - Namibia Medicines Regulatory Council

aventis pharma (pty) ltd - cyclophosphamide - injection - each vial contains 200 mg of cyclophosphamide as dry powder

Namibia - englanti - Namibia Medicines Regulatory Council

aventis pharma (pty) ltd - cyclophosphamide - injection - each vial contains 500 mg of cyclophosphamide as dry powder

Namibia - englanti - Namibia Medicines Regulatory Council

aventis pharma (pty) ltd - cyclophosphamide - injection - each vial contains 1 g of cyclophosphamide as dry powder

Singapore - englanti - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - cyclophosphamide - tablet, sugar coated - 50 mg - cyclophosphamide 50 mg

Filippiinit - englanti - FDA (Food And Drug Administration)

baxter healthcare phils inc - cyclophosphamide monohydrate - powder for injection iv - 200 mg

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter sa-nv - cyclophosphamide monohydrate 214 mg - eq. cyclophosphamide 200 mg - lyophilisate for solution for injection - 200 mg - cyclophosphamide 200 mg - cyclophosphamide

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter sa-nv - cyclophosphamide monohydrate 535 mg - eq. cyclophosphamide 500 mg - lyophilisate for solution for injection - 500 mg - cyclophosphamide 500 mg - cyclophosphamide